MEDVi Tirzepatide Cost: What You'll Actually Pay in 2026

By the Weight Loss Provider Guide Editorial Team Published: April 30, 2026 · Re-verified: August 6, 2026 What we checked: MEDVi's live offer page, MEDVi's terms, MEDVi's cancellation and refund policy, Eli Lilly's official self-pay pricing, FDA records, and current review platforms. We did not complete a checkout.

Disclosure: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission if you use certain provider links on this page. Our conclusions come from the prices, terms, and public records shown below — not from commission size. This page is information, not medical advice.

The MEDVi tirzepatide cost on their live page right now is $166 a month.

Scroll down that same page to the FAQ, and it says $199 a month.

Both spots call the price "locked."

We checked on August 6, 2026. Both numbers were sitting on the same page at the same time.

That's not even the strangest part — and we'll show you the strangest part in a minute. First, here's what you came for.

The short answer

MEDVi's current advertised price for a weekly compounded tirzepatide shot is $166 or $199 per month, depending on which part of their page you read. Older pages and reports from the last 18 months show $249, $279, $299, $349, $399, $449, and $499. Those seven older figures mix oral products, shots, first-month offers, refills, and estimates. They are not nine equal versions of one current price.

MEDVi's own terms say your final charge "may fluctuate contingent upon the prescribed medication and the chosen pharmacy." So there isn't one public price you can safely treat as your final bill. There's a price you get shown.

Who this is good for: People paying cash, with no insurance help coming, who are okay with a compounded medication and who will write down their checkout price before they pay.

Who should skip it: Anyone who needs FDA-approved Zepbound, anyone counting on insurance, and anyone who needs a fixed published number before starting an intake form.

The number that matters most: Whatever your own checkout screen and recurring terms say. Not the ad. Not this page. Screenshot both.

What we actually verified — August 6, 2026

We confirmed these ourselves:

• ✅ MEDVi's live tirzepatide page shows $166/month in the headline and on the product card
• ✅ The FAQ and the "Price-Lock Guarantee" block on that same page say $199/month
• ✅ The FAQ headed "How much does the program cost?" shows raw computer code instead of a price
• ✅ MEDVi's terms allow the final charge to change based on medication and pharmacy
• ✅ MEDVi's cancellation policy requires notice at least 72 hours before your next billing date
• ✅ Eli Lilly's current Self Pay Journey prices for FDA-approved Zepbound are $299 at 2.5 mg, $399 at 5 mg, and a $449 purchase offer at 7.5 mg through 15 mg, with eligibility and refill terms
• ✅ MEDVi's compounded tirzepatide is not an FDA-approved finished drug
• ✅ MEDVi lists three partner pharmacies: Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding
• ✅ MEDVi's terms include binding arbitration for many disputes, with a 30-calendar-day opt-out window after first accepting the terms

Provider-stated vs. independently checked

We could not verify these — treat them as open questions:

• ⚠️ What price actually appears at your checkout
• ⚠️ Whether every visitor is shown the same offer
• ⚠️ Whether the price changes when your dose goes up
• ⚠️ Whether billing runs monthly or every 28 days
• ⚠️ Which pharmacy fills your specific order
• ⚠️ Which states MEDVi currently serves
• ⚠️ Whether needles, syringes, alcohol swabs, and labs are included for you

We did not buy from MEDVi, receive medication, or call their support line. Where we don't know, we say so.

Table of contents

1. MEDVi tirzepatide cost: Is it $166 or $199 right now?
2. Why does MEDVi show two different prices?
3. Will the price go up after the first month?
4. The one thing that would make us walk away
5. What do you actually get for the money?
6. Is MEDVi cheaper than buying FDA-approved Zepbound from Lilly?
7. What this costs over 3, 6, and 12 months
8. When does MEDVi charge your card?
9. How to cancel, whether you get money back, and the arbitration opt-out
10. Is it FDA-approved? Is it legal?
11. What real customers say about the billing
12. Who should use MEDVi — and who should walk
13. Frequently asked questions
14. How we checked all of this

MEDVi tirzepatide cost: Is it $166 or $199 right now?

MEDVi's live tirzepatide page displays $166 per month in its headline and product card, while the FAQ on that same page states $199 per month. Both sections describe the price as locked. Seven more figures from $249 to $499 appear in older MEDVi material, third-party reports, and our own old page, but those sources mix forms, dates, first-month prices, refill prices, and estimates.

Here's every price we could find, where it lives, and how much you should trust it.

The MEDVi Tirzepatide Price Register

Every published figure we found. Checked and labeled August 6, 2026.

Nine published figures. An about three-times spread from bottom to top. Not nine verified current prices.

Notice the $349 row. That's us. Our own page led with $349 until today. We're printing that because a page that audits everyone else's numbers and quietly hides its own isn't an audit — it's marketing.

Why the old numbers aren't lies

Some of those older prices may have been accurate on the day they were written. MEDVi appears to change its offers, and different landing pages or signup flows may carry different deals.

But some reports also mix oral tirzepatide with shots, first-month prices with refill prices, and provider pages with estimates that show no checkout proof.

That's the real problem. It's not that one site is wrong. It's that there is no single public MEDVi tirzepatide price you can use without checking the form, first charge, recurring charge, and date.

Why does MEDVi show two different prices for the same shot?

MEDVi's tirzepatide landing page is internally inconsistent: the hero section and product card show $166 per month while the FAQ and price-lock guarantee on the same page state $199 per month. MEDVi's terms and conditions separately allow the final card charge to vary based on the prescribed medication and the chosen pharmacy. No public documentation explains which figure applies to which customer.

We pulled the page and read all of it. Here's exactly what it says, word for word, section by section.

Three things jump out.

One: the price-lock guarantee doesn't match the product card. The block promising your price will never change quotes $199 for tirzepatide. The tirzepatide product card says $166. Same page. Same moment.

Two: the FAQ that's supposed to answer this exact question is broken. It's showing raw code — \$\{tirinject_sale_price\} — where a dollar amount belongs. The one place MEDVi formally answers "how much does this cost" doesn't answer it at all.

Three, and this is the one nobody else has noticed: look at the words inside that broken code. There's sale_price, and separately there's full_price.

Two slots. One labeled "sale," and one labeled "full."

On a page whose whole promise is "No price hikes. Ever."

We're not going to tell you that proves anything about what you'll be charged. It doesn't. MEDVi's page template has a separate place to put a refill price, but the variable name does not prove that the refill price is higher. It proves the public answer is unfinished.

What we can say with confidence

• Both numbers are live on the page today
• Both are attached to tirzepatide
• Both sections use price-lock language
• The refill FAQ is broken and shows code
• A separate full_price variable exists in the page, but its value is not shown

What we will not guess

We can't tell you, and neither can anyone else writing about this:

• ❌ That $166 is a first-month price and $199 is the refill
• ❌ That one of them is a typo
• ❌ That one applies to a specific dose, state, or pharmacy
• ❌ That every visitor sees the same offer
• ❌ That the lower price will stay locked for you
• ❌ That full_price must be higher than sale_price

Any page that picks one of those explanations and states it as fact is guessing. We don't have evidence for it, so we're not doing it.

The seven questions to get answered before you pay

Copy these. Ask them in the intake chat or by email, and save the reply.

1. What exactly will my card be charged today?
2. What will every charge after that be?
3. How often will I be charged — every month, or every 28 days?
4. Is my rate locked in writing?
5. Does my price change if my dose goes up?
6. Which pharmacy will fill my prescription?
7. What date and time must I cancel by to avoid the next charge?

A screenshot beats a promise you half-remember from an ad. Save the offer page, the checkout total, the recurring terms, and the confirmation email in one folder. If a later charge doesn't match, that folder is your best record of what you were shown.

Will the price go up after the first month?

MEDVi's current tirzepatide page states that the starting monthly rate will not increase and describes the price as locked. However, the same page publishes two different starting rates, its refill FAQ displays unrendered code containing a separate full_price variable, and MEDVi's terms permit the final charge to vary. Multiple third-party reports from 2025 and 2026 describe an introductory rate followed by higher refills of $399 to $499.

Here's the honest read: MEDVi says no. A lot of published reports say yes. We can't settle it from the outside.

What we can do is show you four completely different pricing structures that have been published at different times — because they cannot all describe the same current offer, and which one you're on decides whether your year costs about $2,000 or $5,800.

The four pricing models

These aren't four versions of one current price. They're four different systems published at different times. And the gap between the cheapest and the most expensive is more than $3,700 a year.

That's the finding that matters. You cannot budget for MEDVi tirzepatide until you know which system you're on — and MEDVi's public page does not settle that for you today.

Why some people report a higher second bill

We found reports from people describing exactly this: an ad showing one number, a checkout showing a second, and a renewal showing a third. One Reddit account describes seeing $149 advertised, paying $199, and then facing $399 on the next cycle.

We're using that as a description of what shopping for this feels like, not as proof of MEDVi's billing practices. Those are two different things and we won't blur them.

Possible explanations — all of them possibilities, none confirmed:

• An older pricing structure the person signed up under
• A different promotional landing page
• A different formulation or dose
• A different pharmacy
• A billing period that isn't a calendar month
• A price that was never documented clearly in the first place

The message to send before you pay

"Before I pay, please confirm in writing: the exact charge today, the exact recurring charge, how often it recurs, whether a dose change affects it, and whether the price is guaranteed for as long as I stay enrolled."

If they answer that clearly, you've got what you need. If they won't put it in writing, that's your answer too.

The one thing that would make us walk away

Let's be blunt, because you'd figure this out anyway and you'd trust us less for having danced around it.

MEDVi does not publish one fixed tirzepatide price you can check before you start. Their own page contradicts itself. Their terms let the final charge move. You genuinely cannot know your exact first and recurring charges until your own order summary or written terms show them.

If you need a locked, published number before you spend any time at all — MEDVi is the wrong choice, and Ro is the better one. Ro publishes its membership pricing openly: $39 for the first month, then $149/month, or as low as $74/month if you pay for a year upfront. Ro offers FDA-approved Zepbound. The medication is a separate charge, but the membership price is public. If that's what you need, go there instead — and we mean that.

But here's why the rest of you should keep reading.

MEDVi's compounded program doesn't bill insurance. At all. That means no formulary, prior authorization, denial letter, appeal, or pharmacy-benefit-manager wait on this compounded path. But it is still an auto-renewing cash-pay subscription, and the exact first and recurring charges need to be verified.

For someone with no coverage — or with a plan that excludes weight-loss drugs — that trade is the entire point. And when MEDVi's locked rate is real at $166 or $199, it is lower than Lilly's $299 starting-dose price, $399 5 mg price, and $449 higher-dose purchase offer.

That's a big deal. It's just a big deal you have to verify for yourself, in your own checkout, before you pay.

➡️ Settle your own number before you pay

Before submitting payment, look for the first charge, recurring charge, billing cycle, and next billing date. If the page does not show them, ask support to confirm them in writing before you pay.

See MEDVi's current tirzepatide page and check your eligibility →

A licensed clinician decides whether treatment is appropriate. Screenshot the price, recurring terms, billing interval, and cancellation date before you pay.

What do you actually get for the money?

MEDVi's published tirzepatide offer states that the monthly price includes clinician review, a personalized care plan, one-on-one guidance, the medication itself when prescribed, ongoing support, and free expedited shipping, with no separate membership fee on the compounded path. Several cost items — including required lab work, injection supplies, and state-specific charges — are not clearly addressed on MEDVi's public pages.

What MEDVi says is included

What nobody has confirmed

That second table is longer than the first. We'd rather show you that than pretend.

One thing worth understanding: "no membership fee" is not "no subscription"

MEDVi's compounded tirzepatide offer genuinely doesn't itemize a separate membership charge. Good.

But their own cancellation policy calls the program a subscription service. It renews automatically. You are signing up for a recurring charge that keeps going until you actively stop it.

Those two facts sit together fine. Just don't read "no membership fee" as "no auto-renew," because it isn't.

Is MEDVi cheaper than buying FDA-approved Zepbound from Lilly?

Eli Lilly's current Self Pay Journey terms list FDA-approved Zepbound at $299 for 2.5 mg, $399 for 5 mg, and a $449 purchase offer for 7.5 mg through 15 mg, with eligibility and refill terms. If MEDVi truly stays at $166 or $199 for your account, MEDVi is cheaper. If your MEDVi refill is $399 to $499, as older reports describe, the discount shrinks or disappears.

This is the section that might change your mind.

A list-price comparison can make compounded tirzepatide look cheaper than it is. Lilly now publishes lower Self Pay Journey prices by dose.

Here's what Lilly actually charges eligible cash patients today under the current program terms.

MEDVi compounded vs. Lilly's official self-pay price

Zepbound figures come from Eli Lilly's current Self Pay Journey Program terms. A "month" means 28 days — four single-dose vials or one KwikPen. To keep the $449 purchase offer at 7.5 mg through 15 mg, the next refill purchase must be completed within 45 days of the prior delivery. If it is late, the published regular price is $499 at 7.5 mg and $699 at 10 mg through 15 mg. Lilly may change or end the offer at any time. Eligibility and other restrictions apply.

Read that table again, because it's the whole ballgame

Zepbound starts at 2.5 mg for four weeks. The labeled next step is 5 mg. Later increases depend on response and tolerability.

Under MEDVi's current $166–$199 public promise, the compounded discount does not run out at 5 mg — if that rate really stays flat for your account. Under the older $399–$499 refill reports, the discount shrinks or disappears.

If your MEDVi charge lands near $449, one option went through FDA review for safety, effectiveness, and quality. The other didn't.

Now the other side, because it's just as true. If MEDVi's locked rate is real for you at $166 or $199, you're paying less than Lilly's current Self Pay Journey price at every dose. Across an illustrative first-year path of one $299 fill, one $399 fill, and ten $449 fills, the gap is about $2,800 to $3,200. It's a genuinely great deal on price.

So the answer to "is MEDVi cheaper" is: it depends entirely on the MEDVi price and recurring terms you actually get. At $166–$199, it's not close — MEDVi wins on cash price. At $399–$499, you may be paying FDA-approved brand-name money for a product that isn't the brand.

That's why this page exists. For the full side-by-side, see MEDVi vs. Zepbound.

➡️ If you're headed for a maintenance dose, check this first

Before you commit to a compounded plan, find out whether the FDA-approved version is within reach. Your plan may cover it, may require prior authorization, or may exclude it. Check before paying cash. For the full cash-price path, see Zepbound cost without insurance.

Ro offers FDA-approved Zepbound and a free insurance coverage checker. Membership is $39 for the first month, then $149/month, or as low as $74/month with an annual plan paid upfront. Medication is billed separately. The free checker reports coverage, estimated cost, and whether prior authorization may be required; it does not submit a treatment request or write a prescription.

Check your Zepbound coverage with Ro →

Free coverage check. Coverage, treatment eligibility, and prescription approval aren't guaranteed. Membership and medication are separate charges.

What MEDVi tirzepatide costs over 3, 6, and 12 months

At MEDVi's advertised $166 per charge, twelve charges total $1,992. At the $199 figure published on the same page, twelve charges total $2,388. Under the introductory-plus-refill structures reported by older third-party sources, twelve charges total $4,668 to $5,768. These are calculations from published figures, not from a completed transaction.

Nobody signs up for one month. So let's do the math you'd actually need.

The first four rows count charges, not guaranteed calendar months. If MEDVi bills on the same date each month, 12 months usually means 12 charges. If it bills every 28 days, the first 12 calendar months can contain 14 charges when the first charge is counted — two more than monthly billing. We could not confirm MEDVi's current billing interval, so ask.

The two numbers on MEDVi's own page are $396 apart

$166 versus $199 sounds like pocket change. Over twelve charges it's:

• $33 each charge
• $198 over six charges
• $396 over twelve charges

That's not a rounding error. That's a real amount of money riding on which part of MEDVi's page turns out to be right for you.

Build your own number

Enter what your screen shows — the first charge, the recurring charge, the billing interval, and the first billing date. The checker returns:

• Your 3-, 6-, and 12-calendar-month total
• Your real effective monthly cost
• How many charges fall in each window
• Your next three billing dates
• How your offer compares with MEDVi's public $166 and $199
• A warning if your first and recurring prices differ
• A warning if no recurring price was shown at all
• An estimated 72-hour cancellation deadline and a safer four-day reminder
• A printable "before I pay" record with all your terms in one place

An AI summary can tell you "$166 to $499." It can't see the private offer sitting in your browser session right now, or tell you which date to put in your calendar.

➡️ Get your number, then decide

You've got the math. Now go get the one input only you can see.

View MEDVi's live pricing and start the eligibility check →

Do not submit payment until you have written down the first charge, recurring charge, billing interval, and next billing date.

When does MEDVi charge your card — and what if they say no?

Under MEDVi's published cancellation policy, the subscription begins once the intake is completed and the first month is paid, while an independent clinician separately decides whether to prescribe. Payment does not guarantee a prescription. MEDVi's policy states that a customer who is medically disqualified at the start receives a full refund.

This is the part most people miss, and it surprises them at a bad moment.

You pay before a clinician approves you.

Here's the actual order of events:

1. You fill out the medical intake form
2. You enter payment and get charged
3. MEDVi routes your file to an independent clinician
4. The clinician decides whether treatment is appropriate for you
5. If yes, the prescription goes to a partner pharmacy
6. Medication ships
7. The subscription renews automatically unless you cancel

Paying is not the same as being approved. A licensed clinician makes an independent call based on your medical history. Some people get turned down.

If a clinician says you don't qualify

MEDVi's written policy says medical disqualification at the start gets a full refund. That's the good news, and it's a reasonable policy.

MEDVi separately says that if a clinician later decides you are no longer eligible, the subscription will be canceled and a refund may be issued. "May" is not a promise.

Do this anyway:

• Save the disqualification notice
• Ask for refund confirmation in writing
• Write down the amount and the date they say it'll process
• Follow up through both the patient portal and their email address if it doesn't arrive

If you just change your mind

Different rules. Completely different rules.

Once you've received services — including a consultation — the refund picture changes. There is no universal free trial here. Don't assume you can back out on day 10 and get everything back. Read the next section before you pay, not after.

How to cancel MEDVi, whether you get money back, and the arbitration opt-out

MEDVi's published policy allows cancellation by email to hello@medvi.org or through patient portal chat, and requires the request to arrive at least 72 hours before the next billing date to stop the next charge. Payments for the current or previous monthly billing periods are generally not refunded, though initial medical disqualification, a very early no-service cancellation, and unshipped months in certain prepaid plans are treated differently.

Know your exit before you take the entrance. Especially with an auto-renewing subscription.

The steps

1. Find your next billing date. Do this the day you sign up, not the week it hits.
2. Send your cancellation more than 72 hours before it. This is the rule that catches people.
3. Use both channels — portal chat and email — so you have two records.
4. Say the word "cancel," not "pause." They're not the same request.
5. Ask for the effective cancellation date in writing.
6. Ask for written confirmation that no more charges will occur.
7. Save the screenshots and the sent email.
8. Check your account again just before the old renewal date would have hit.

Copy this email

Subject: Cancel my MEDVi subscription

Please cancel my MEDVi subscription effective before my next billing cycle. This is a cancellation, not a pause. Please confirm in writing: the effective cancellation date, my final service date, and that no further recurring charges will be made to my card.

What gets refunded and what doesn't

One more deadline: 30 days to opt out of arbitration

MEDVi's terms say many disputes must go to binding arbitration and include a class-action waiver. The same terms let you opt out by emailing help@medvi.org within 30 calendar days of first accepting the terms.

The notice must come from the email tied to your account and include your first and last name, address, account email, and a clear statement that you decline the arbitration clause.

Subject: Arbitration clause opt-out

I am opting out of the Arbitration Clause in MEDVi's Terms and Conditions. My name is [full name]. My address is [address]. The email tied to my account is [email]. I clearly decline the Arbitration Clause. Please confirm receipt.

This is a contract term, not legal advice. Save the sent email and delivery record.

Why we're spending this much space on cancellation

Because MEDVi's Better Business Bureau profile currently shows an F rating, 682 complaints, and failure to respond to 100 complaints.

That doesn't mean every complaint is accurate, and it doesn't predict your experience. But it does mean the paperwork above isn't paranoia. It's the cheapest insurance available, and it takes four minutes.

➡️ You know the exit. Now check the entrance.

The cancellation window is at least 72 hours before renewal. Put a reminder in your phone for four days before your first renewal date, not exactly three. That gives you room for the time of day and reduces the recurring-charge risk.

Check MEDVi eligibility and see the current public price →

Save your first charge, recurring charge, renewal date, 72-hour cutoff, and cancellation confirmation in one folder.

Is MEDVi's tirzepatide FDA-approved? Is it even legal in 2026?

MEDVi's tirzepatide offer is a compounded medication, not FDA-approved Zepbound or Mounjaro. FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients. The broad shortage-based compounding window ended in 2025. Patient-specific compounding can still occur under Section 503A when its conditions are met, while Section 503B outsourcing facilities face separate limits on bulk tirzepatide.

Short answer: it is not FDA-approved, and the rules around it got a lot narrower in 2025.

Compounded vs. FDA-approved, plainly

"Compounded" means a pharmacy or other qualified compounder prepares a medication under federal and state compounding rules. It may be made for an identified patient or for certain health-care settings, depending on the legal path.

But FDA does not review compounded drugs before they go out. No FDA premarket review for safety. No FDA premarket review for effectiveness. No FDA premarket review for quality or strength.

FDA-approved Zepbound went through all three.

We're not going to tell you compounded is "the same." It isn't, and any page that says so is either careless or hoping you won't check. For the full provider-specific record, see our MEDVi FDA-status check.

What changed in the law

The timeline matters, so here it is straight:

• October 2, 2024 — FDA first declared the tirzepatide shortage resolved
• December 19, 2024 — FDA re-evaluated and reaffirmed that decision
• February 18, 2025 — FDA's shortage-based enforcement-discretion period ended for Section 503A pharmacies and physicians
• March 19, 2025 — The matching period ended for Section 503B outsourcing facilities
• May 7, 2025 — A federal district court granted summary judgment to FDA and Lilly in the shortage-list challenge
• March 30, 2026 — The Fifth Circuit heard oral argument in the appeal; we found no published appellate decision when we checked on August 6, 2026
• April 30, 2026 — FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the Section 503B bulks list; we found no final determination when we checked on August 6, 2026

What that means for you: compounded tirzepatide did not become automatically illegal everywhere. But the blanket shortage route is over.

Under Section 503A, compounding generally uses a valid prescription for an identified patient. Limited advance preparation may occur based on a compounder's prescription history. A compounder also cannot regularly or in large amounts make what FDA treats as an essential copy of an available approved drug, unless a prescriber determines and documents a change that produces a significant difference for that identified patient.

Under Section 503B, an outsourcing facility generally may use a bulk drug substance only when it is on the 503B bulks list or the compounded drug is on FDA's shortage list. Tirzepatide is currently on neither list.

FDA also tells patients and clinicians that compounded drugs should be used when a patient's medical needs cannot be met by an FDA-approved drug. A lower price by itself is not the product change described in FDA's significant-difference test.

This belongs on a cost page because the cheapest option is worth nothing if it disappears mid-treatment. That's a real risk with a compounded GLP-1 plan right now, and it's a reason not to prepay twelve months if you can avoid it.

The FDA adverse-event count

As of May 31, 2026, FDA said it had received more than 730 adverse-event reports associated with compounded tirzepatide.

That number needs context:

• It covers compounded tirzepatide broadly, not MEDVi specifically
• FDA says it is not always possible to tell whether the drug caused the event
• Many reported events look like known events with FDA-approved versions
• State-licensed pharmacies that are not outsourcing facilities generally do not have to send adverse-event reports to FDA, so FDA says underreporting is likely
• FDA has also warned about dosing mistakes, doses beyond approved labeling, warm shipments, and fraudulent labels in the broader compounded GLP-1 market

That is not a reason to panic. It is a reason to know the pharmacy, read the label, check the dose, and contact the prescriber when something looks wrong.

The February 2026 FDA warning letter

On February 20, 2026, FDA issued warning letter 721455 to MEDVi, LLC. The agency said it reviewed MEDVi's website content in December 2025 and found false or misleading promotion and website labeling involving compounded semaglutide and tirzepatide products.

Be precise about what that is and isn't:

• ✅ It was about website labeling and promotion — how the products and compounder were described
• ❌ It was not a recall
• ❌ It was not a finding of contamination
• ❌ It was not a finding of patient harm

MEDVi published a response in April saying the flagged content sat on a domain run by an affiliate marketing agency and contained outdated copy. That's MEDVi's position. We're reporting it alongside FDA's letter, not instead of it.

FDA's public warning-letter page did not show a close-out letter when we checked on August 6, 2026, so the agency had not publicly marked the matter closed.

What real MEDVi customers say about the billing

MEDVi's public reputation differs sharply by platform. Trustpilot showed a 4.4 rating across 14,348 reviews, with 80% five-star and 11% one-star, when checked on August 6, 2026. The Better Business Bureau showed an F business rating, 682 complaints, failure to respond to 100 complaints, and a 1.9 average across 578 customer reviews. Neither platform proves the medical or billing details of an individual account.

Two platforms. Two very different pictures. You should see both.

Three real reviews

"So far everything is going along well and the support calls have been helpful." — Robin Catalde, Trustpilot, August 5, 2026

"Watch your charges very carefully." — Kaitlyn G, BBB review, July 21, 2026

And from Reddit, described rather than quoted: one person recounted seeing $149 advertised, being charged $199, and then facing $399 on the next cycle. We're including it because it's exactly the experience this page is built to prevent — not as proof of how MEDVi bills every customer.

About these reviews: These are individual customer accounts. They do not establish typical results, medical effectiveness, safety, or what your experience will be. We have not independently verified the facts behind any individual review.

What we make of it

Not "Trustpilot proves MEDVi is great." Not "the BBB proves it's a scam." Both of those readings are lazy.

Here's the honest version:

• Thousands of people report a smooth experience. 14,348 reviews at 4.4 is a real signal, and MEDVi actively responds when people complain publicly.
• A meaningful group reports billing, shipping, and cancellation problems. 682 BBB complaints is a lot, and failure to respond to 100 is worse than the raw count alone.
• Many visible complaints concern money and fulfillment. Charges, renewals, shipping, cancellation, and refunds come up often. We did not code all 682 complaints, so we will not pretend every one fits the same bucket.
• Some of that billing risk is reducible. A screenshot, written recurring terms, and a calendar reminder give you a better record.

Which is the whole argument of this page: the billing risk we can help you reduce isn't mysterious. It's administrative. And administrative risk is the kind you can protect yourself against.

➡️ If the terms work for you, take the next step

You've seen the price spread, the trade-offs, the exit rules, and the public record. If a documented $166–$199 recurring rate lands in your checkout and you're comfortable with a compounded medication, this is a reasonable cash-pay path — and it is cheaper than Lilly's current Self Pay Journey prices. Insurance may still make FDA-approved treatment cheaper, so check that first if you have coverage.

Check MEDVi availability and see the current public price →

Confirm your first charge, recurring charge, billing interval, assigned pharmacy, and cancellation date before you pay. A licensed clinician makes the treatment decision.

Who should use MEDVi — and who should walk away

MEDVi's compounded tirzepatide fits cash-paying adults who receive a clearly documented recurring rate near $166 to $199, accept that the medication is not FDA-approved, and are willing to track an auto-renewing subscription. It is a poor fit for anyone who requires FDA-approved Zepbound, needs insurance support, or cannot get a written recurring price before paying.

MEDVi may fit you if…

• You're paying cash and insurance isn't coming to the rescue
• You understand this is compounded, not FDA-approved, and you're okay with that
• Your checkout shows a price you can afford — and shows the recurring price too
• You're willing to screenshot terms and set a cancellation reminder
• You want one bundled price instead of separate charges for visits, drugs, and shipping
• You'd rather use a cash-pay path than fight through an insurance prior authorization

Walk away if…

• You need FDA-approved Zepbound specifically → go to Ro
• You have insurance you haven't tested yet → run Ro's free coverage check first
• You're uncomfortable with compounded medication → that instinct is reasonable, honor it
• Your checkout doesn't clearly show the recurring price → stop and ask before paying
• The price you're shown doesn't match what you were promised and support won't clarify → walk
• You can't comfortably afford the charge for several months → this is a long treatment, not a one-month purchase
• You want guaranteed approval → nobody can offer that; a clinician decides

Find yourself in this table

Our verdict

MEDVi is a strong cash-pay option when your own written recurring terms lock the price at $166–$199. We'd start only after the first charge, recurring charge, billing interval, cancellation date, assigned pharmacy, and compounded status are all visible to you in writing.

At $399–$499, the math changes and you should seriously look at FDA-approved Zepbound instead, because the cash prices can be the same or lower.

That's a conditional yes. We can't give an unconditional one while MEDVi's own page shows two prices — and we'd be doing you a disservice if we pretended otherwise.

Frequently asked questions

How much does MEDVi tirzepatide cost per month? MEDVi's live page shows $166 per month in the headline and $199 in the FAQ. Confirm the first charge, recurring charge, and billing cycle in your own checkout before paying.

Is it $166 or $199? Both appear on the same page right now. We haven't completed a checkout, so the amount shown and documented in your own session is the one that matters.

Does the price go up after the first month? MEDVi advertises a price lock. But the page gives two prices, its refill FAQ shows raw variables, its terms let the final card charge vary, and older reports describe refills of $399–$499. Get the recurring number in writing.

Does the price go up when my dose goes up? MEDVi's current page says the price is locked and does not describe a dose-based increase. Older third-party reports describe dose-tiered pricing, while a July 2026 third-party signup capture described a flat $399 ongoing rate. Ask directly, and get the answer in writing.

How often does MEDVi bill? We could not verify whether the current tirzepatide offer bills on the same calendar date each month or every 28 days. Ask before paying. A true 28-day cycle can create 14 charges in the first 12 calendar months when the first charge is counted.

Is there a membership fee? Not on the compounded tirzepatide offer, according to MEDVi's page. Their brand-name Wegovy and Zepbound paths work differently — $99/month membership plus the cost of the drug.

Is the medication included in the price? Yes, when a clinician determines it's appropriate and writes a prescription. Paying does not guarantee you'll be prescribed anything.

Are needles, syringes, alcohol swabs, and labs included? MEDVi's public tirzepatide page does not clearly settle every one of those items for every customer. Ask what your exact order includes.

Will I be charged before a clinician approves me? Yes. Payment comes before the clinical decision. MEDVi's policy says an initial medical disqualification gets a full refund.

Does MEDVi take insurance? No for the compounded program. MEDVi says its affiliated medical groups are out of network, and the compounded path is cash-pay.

Can I use HSA or FSA funds? MEDVi advertises HSA/FSA eligibility. That's not a universal tax ruling — check with your plan administrator and keep an itemized receipt.

How do I cancel? Email hello@medvi.org or use the patient portal chat at least 72 hours before your next billing date. Ask for written confirmation that the account is canceled, not paused.

Do I get a refund if I cancel? Initial medical disqualification gets a full refund. Canceling in the first 72 hours with no subscription services received also gets a full refund. Current and prior monthly periods are not refunded just because you cancel. If you were charged for two or more months at once, MEDVi says it refunds months for which no medication was shipped.

Can I opt out of MEDVi's arbitration clause? MEDVi's terms say yes, if you email help@medvi.org within 30 calendar days of first accepting the terms and include the required identifying details and a clear opt-out statement.

Is MEDVi tirzepatide FDA-approved? No. It's compounded. FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients.

Is it the same as Zepbound? No, and don't let anyone tell you it is. Zepbound is an FDA-approved finished drug that went through premarket review. MEDVi's compounded tirzepatide did not.

Is compounded tirzepatide still legal in 2026? It can be compounded when the conditions of the applicable federal and state rules are met, but the broad shortage-based route ended in 2025. Section 503A requires patient-specific prescribing and limits regular compounding of essential copies; Section 503B has separate bulk-substance and copy restrictions.

Which pharmacy does MEDVi use? Their public terms list Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding. Which one fills your order isn't published for every customer — ask.

Is MEDVi available in my state? MEDVi requires you to live in a place where the clinician and pharmacy can legally serve you, but the current tirzepatide page does not publish a clear state-by-state list. Confirm during intake.

Is it worth it? At a documented $166–$199 recurring charge, for someone paying cash who accepts compounded care — yes, it's a strong value. At $399–$499, look hard at FDA-approved Zepbound first, because the cash price may be the same or lower.

How we checked all of this

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. For this page, we reviewed MEDVi's live public offer page, MEDVi's terms and conditions, MEDVi's cancellation and refund policy, Eli Lilly's official Zepbound self-pay program terms, FDA warning-letter and compounding records, the current federal court record, and current data from Trustpilot and the Better Business Bureau on August 6, 2026.

Where our facts came from, in order of weight

1. MEDVi's live tirzepatide offer page, fetched and read in full
2. MEDVi's official terms and conditions
3. MEDVi's official cancellation and refund policy
4. Eli Lilly's official Zepbound Self Pay Journey Program terms
5. Official Zepbound dosing information
6. FDA's current 503A and 503B compounding clarification
7. FDA's current concerns about unapproved GLP-1 drugs
8. FDA's April 30, 2026 proposed 503B bulks-list exclusion
9. FDA warning letter 721455
10. MEDVi's published response to the warning letter
11. Federal court orders and the Fifth Circuit's March 30, 2026 oral-argument calendar for case 25-10600
12. Ro's official membership pricing
13. Ro's official free insurance coverage checker
14. MEDVi's Trustpilot profile
15. MEDVi's BBB business profile
16. MEDVi's BBB customer-review page
17. Dated third-party price reports, labeled as historical, customer-reported, or competitor-captured — never treated as current checkout proof
18. Reddit — used only for how one person described the problem, never as evidence of a company-wide billing rule

What we did not do

• We did not complete a checkout
• We did not buy or receive medication
• We did not inspect any product
• We did not call MEDVi's support line
• We did not verify any individual customer review
• We are not claiming any customer's experience is typical
• We did not treat an older third-party price as a current MEDVi checkout price

Corrections log

Why you can check our work

Every major number on this page has a named source and a date. Where we don't know something, we say so instead of filling the gap. You can also read our editorial standards and corrections policy.

That's the whole method. It shouldn't be unusual, but on this topic it is.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Get my personalized GLP-1 action plan →

About a minute. No signup. It asks about your insurance situation, your budget, whether you want FDA-approved or compounded care, and what state you're in — then tells you which path fits those answers.

Three paths from here

🟢 "I understand compounded care and my price is documented." Check MEDVi eligibility →

🔵 "I want FDA-approved Zepbound or help checking insurance." Check coverage with Ro →

⚪ "I don't know which route fits me." Take the free matching quiz →

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page is for information only and is not medical advice. Prescription treatment requires evaluation by a licensed clinician, who decides whether any medication is appropriate. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Prices and program terms change — always confirm the first charge, recurring charge, billing cycle, pharmacy, and current terms before paying.

Last verified: August 6, 2026